Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why [Yahoo! Finance]
Agios Pharmaceuticals, Inc. (AGIO)
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.agios.com/investor-overview
Company Research
Source: Yahoo! Finance
Shares of Agios Pharmaceuticals AGIO have plunged 23% over the past six months, primarily due to pipeline and regulatory setbacks, which have dampened investor confidence in the company's near-term growth prospects. Agios Pharmaceuticals currently derives revenues solely from its lead drug, mitapivat. The drug is approved for the treatment of hemolytic anemia in adult patients with pyruvate kinase (PK) deficiency under the brand name Pyrukynd. AGIO is also developing mitapivat as a potential therapy for sickle cell disease (SCD) and thalassemia indications. Over the past year, the stock has lost 8.8% against the industry's 12.7% growth. Zacks Investment Research Image Source: Zacks Investment Research Mixed Phase III Data on Mitapivat Study in SCD Reduced Confidence in AGIO In November 2025, the company reported mixed top-line data from the phase III RISE UP study, which evaluated orally administered mitapivat in patients aged 16 years or older with SCD. While the study
Show less
Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGIO alerts
High impacting Agios Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AGIO
News
- ATTENTION AGIO SHAREHOLDERS: Investors who lost money on Agios Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigationPR Newswire
- Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact The Gross Law Firm Regarding an Ongoing InvestigationPR Newswire
- Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact Levi & Korsinsky Regarding an Ongoing InvestigationPR Newswire
- Agios Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact The Gross Law Firm for Details- AGIOPR Newswire
- Agios Pharmaceuticals: Worthy Of Accumulation [Seeking Alpha]Seeking Alpha
AGIO
Earnings
- 2/12/26 - Miss
AGIO
Sec Filings
- 3/9/26 - Form 4
- 3/5/26 - Form 144
- 3/5/26 - Form 4
- AGIO's page on the SEC website